Bortezomib (Velcade) for Multiple Myeloma
Bortezomib (PS341; Velcade Millenium), the first proteasome inhibitor, has received accelerated approval from the FDA for treatment of refractory multiple myeloma. This review includes descriptions of the mechanism of action, pharmacokinetics, adverse effects, and dosage and cost of bortezomib, outlines the results of clinical studies, and concludes with an overall assessment of the drug's effectiveness....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Bortezomib (Velcade) for Multiple Myeloma
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1161
Article Code: 1161a
Date: July 21, 2003
Volume: 45
Pages: 57-68
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1161
Article Code: 1161a
Date: July 21, 2003
Volume: 45
Pages: 57-68
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)